PIM
RLAY icon

Platinum Investment Management’s Relay Therapeutics RLAY Stock Holding History

Platinum Investment Management’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-2,000
Closed -$85K – 152
2020
Q3 		$85K Buy
+2,000
New +$76.3K ﹤0.01% 127

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

Platinum Investment Management's RLAY Position: Q4 2020 in Review

Platinum Investment Management sold out of Relay Therapeutics (RLAY) in Q4 2020, closing a stake of 2,000 shares — an estimated $85K sold.

Platinum Investment Management first reported a position in RLAY in Q3 2020 and held it in 1 quarter. The position peaked at $85K in Q3 2020. 115 funds tracked by Wall St. Rank hold RLAY as of Q4 2020.

  • Platinum Investment Management reported no remaining Relay Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Platinum Investment Management sold 2,000 Relay Therapeutics shares in Q4 2020, an estimated $85K.
  • Platinum Investment Management first reported a position in Relay Therapeutics in Q3 2020 and held it in 1 quarter.
  • Platinum Investment Management's Relay Therapeutics position peaked at $85K in Q3 2020.
  • 115 funds tracked by Wall St. Rank held Relay Therapeutics as of Q4 2020.

Based on Platinum Investment Management's 13F filing for Q4 2020, filed 12 Feb 2021.